Get some practical advice on how to diagnosis and treat bipolar disorder, in an interview with Claudia Baldassano, MD, director of the bipolar outpatient program at the University of Pennsylvania.
Read More
Learn about the use of transference-focused psychotherapy to treat personality disorders, in an interview with Kenneth N. Levy, PhD, from the Personality Disorders Institute at Cornell University.
Read More
Inflammation is hot, both literally and figuratively. The medical literature is replete with studies implicating inflammation as a possible root cause of diseases as varied as heart disease, cancer, Alzheimer’s disease, depression and, of course, arthritis. A recent meta-analysis of all randomized controlled studies for depression yielded some intriguing results.
Read More
Transient ischemic attacks (TIAs)—commonly referred to as “mini-strokes”—don’t leave people with any permanent neurological symptoms, but in some individuals they may lead to post-traumatic stress disorder (PTSD) for the event, according to a new study.
Read More
It’s commonly known that the risk of developing dementia is related to education level, history of head trauma, family history, and genetics. But could personality also play a role?
Read More
In bipolar disorder, depression is often the neglected stepchild. Mania gets more attention, perhaps because it presents so dramatically. Imagine two bipolar patients in an emergency room: one withdrawn and depressed, sitting quietly, and another ranting and pacing the room. Which one would be seen first?
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three...